Summary
22 / 100 · Bulios Score
What speaks for it
None of the indicators we track stands out on the positive side.
What to watch
- Revenue fell by 25% a year over the last 3 years.
- The company made a loss over the last 12 months.
- It missed profit estimates 5 times in the last 8 quarters.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 5.1% a year over 5 years. Over the last 3 years it fell by 25% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $7.62M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 1
- Sell 0
Today's price within the analysts' price targets
The average target of $3 is 783% above today's price. 50% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Grant 60%
- Research and Development 31%
- License 8.6%
By region
The company reports no revenue by region.
Grant brings in 60% of revenue. License grew fastest, by 2.4% a year.
Segments in detail